Thomas Bourquard ^UDM

Thomas Bourquard serves as the Chief Science Officer and co-founder of MAbSilico, a TechBio company specializing in AI-based solutions for antibody drug design and discovery. With a background in polymers and composites, particularly in special purpose vehicles, Thomas brings expertise in materials such as ceramics, ceramic compounds, glass containers, metals, and various techniques like rheological methodologies. His combination of research experience and business expertise provides a comprehensive understanding of the field. MAbSilico's mission is to develop solutions that solve customer problems, benefiting both customers and the community. The company's focus includes epitope mapping, cross-reactivity evaluation, and alternative antibody identification. MAbSilico stands out as the only TechBio providing computationally designed antibodies through AI, with associated biological validations. The company assists biotech and pharma companies in mitigating antibody discovery risks by delivering computational candidates within days, designed, and characterized in silico, and validated using cutting-edge biological technologies. MAbSilico utilizes a combination of 3D modeling, interaction simulation, and linear sequences analysis to define antibody drug candidates based on epitope, affinity, off-target risk, cross-species reactivity, and developability assessment, ensuring readiness for biological activity evaluation. NLP technologies are employed to gather information about antibodies and their targets in different databases, ensuring competitive landscape analysis and assessing the freedom to operate for computationally designed antibody candidates.